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Objective: The goal of this study was to evaluate valvular functionality after transcatheter pulmonary valve
replacement in sheep using a novel pulmonary valve stent.
Methods: Fresh porcine pericardium cross-linked with 0.6% glutaraldehyde was treated with L-glutamine to
eliminate glutaraldehyde toxicity and sutured onto a valve ring before mounting on a nitinol stent to construct
the pulmonary valve stent. Percutaneous femoral vein transcatheter pulmonary valve replacement was performed
with the newly constructed valve stent. Pulmonary valve stents were implanted in 10 healthy sheep (6 males and
4 females) weighing an average of 25.7  4.1 kg. Color Doppler echocardiography, 64-row computed tomogra-
phy, and direct catheter examination were used to assess valvular function.
Results: Implantation was successful in 8 sheep. Shortly after surgery, all artificial valve stents exhibited normal
open and close functionality and no stenosis or insufficiency. Heart rate was slightly elevated at this time, while all
other hemodynamic parameters were normal. Six-month follow-up revealed no evidence of valve stent disloca-
tion and normal valvular and cardiac functionality. There was no evidence of stent fracture. Repeated valve stent
implantation was well tolerated as indicated by good valvular functionality 2 months postdelivery.
Conclusion: The novel pulmonary valve stent described herein can be delivered via percutaneous femoral vein
transcatheter implantation and is highly efficacious at 6 months postdelivery. Furthermore, repeated valve stent
replacement was successful.
Zong et al Congenital Heart DiseaseFrom the earliest transcatheter valve replacement experimen-
tal study performed by Andersen and colleagues in 1992,1 to
Bonhoeffer and colleagues’ pilot study of percutaneous pul-
monary valve replacement in a right ventricle–to–pulmonary
artery prosthetic conduit with valve dysfunction in 2000,2
pulmonary valve replacement technology has steadily ad-
vanced.3-5 Clinically, this technique appears to offer signifi-
cant benefits over standard surgical procedures for patients
with congenital heart diseases requiring additional surgical
intervention.6,7 Not only is the process efficacious and less
traumatic, but the duration of hospital stay is shortened.6
Despite the fact that the use of percutaneous pulmonary
valve transplantation has been readily adopted, various
problems associated with stent implantation per se have
been reported. These include stent fracture, valve disloca-
tion, and restenosis.8-12 In addition, as outlined by Attmann
and colleagues,13 currently available stents are not suitable
for use in all prospective patients due to anatomic variability.
Hence there is a definite need for continued development
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tively recent technique.
Here we report on the design and use of a novel valve stent
device for transcatheter pulmonary valve replacement. This
study was performed using an ovine experimental model.
Immediate postoperative functional analysis was assessed
using color echocardiography, and a comprehensive fol-
low-up evaluation was performed at 6 months using color
echocardiography, 64-row computed tomography (CT),
and direct catheter examination.
METHODS
Valve Stent Construction
The valve stent was constructed using an artificial valve and a conduit-
shapedstent.Theartificial stentwasconstructed fromavalve leafletandavalve
ring. The valve ring was made of supermalleable nitinol wire (Shanghai Mal-
leable Alloy Company, Shanghai, China) with a radial diameter of 0.25 mm,
bent into 3 crescent shapes, and connected by a nitinol holder (see Figure 1,A).
Porcine pericardium was used for valve leaflet creation following removal of
surface fat tissue, agitated digestion with 0.01% trypsin for 8 hours, subse-
quent cross-linking with 0.6% glutaraldehyde for 36 hours, and, finally, re-
peated washing with 2% L-glutamine (to eliminate glutaraldehyde toxicity).
Pericardium tissuewas trimmed into 3 identically shapedvalve leaflets accord-
ing to the valve model profile and sutured onto the valve ring using 7–0 poly-
propylene thread (Johnson and Johnson, New Brunswick City, NJ). The
attached side was denoted as the attachment margin and the nonattached
side, the margo liber. The completed artificial valve is depicted in Figure 1, B.
The conduit-shaped stentwas constructedwith supermalleablenitinolwire
with a diameter of 0.18mmandwas comprised of 3 parts: the head, neck, and
body. The head portionwas proximal to the heart end, slightly protruded, and
trumpet shaped. The neck portionwas thinner and connected the head portion
with the body portion. The body portion was straight and tubular shaped.
The artificial valve was fixed inside the conduit-shaped stent, with the arc
tips facing toward the top of the head portion and the sides attached to therdiovascular Surgery c Volume 137, Number 6 1363
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DAbbreviations and Acronyms
CT ¼ computed tomography
DSA ¼ digital subtraction angiography
neck portion, both of which were sutured with 5–0 polypropylene thread
(Figure 1, C shows the completed valve stent). The valve stent was pre-
served in 60% ethanol, sterilized with 75% ethanol for 12 hours, and
washed 3 times with saline prior to placement. Figure 2, A and B, shows
the valved stent crimped by hand and then loaded into a 14-French sheath,
respectively.
Animals
Animal studies were approved by the local hospital ethics committee. All
animals received care in compliance with the Guide for the Care and Use of
Laboratory Animals (www.nap.edu/catalog/5140.html). Ten healthy sheep
(6 males and 4 females), 12 to 16 months old and weighing an average of
25.7  4.1 kg, were used. Preoperative electrocardiogram, chest film, and
color echocardiographic examinations revealed no abnormalities. No car-
diac murmurs were detected. Animals were fasted and water deprived for
8 hours before surgery. Anesthesia was initiated by intramuscular injection
of ketamine (10 mg/kg body weight), followed by intravenous injection of
10 mL of 2.5% pentobarbital sodium. Hair was removed from the precor-
dial region and the inner sides of the extremities.
Valve Stent Implantation and Postoperative
Treatment
After sterilizing the skin in the inguinal region, a 6-French leak-proof
sheath was introduced percutaneously via the left femoral vein. An incision
was made through the right inguinal skin and subcutaneous tissue, and the
right femoral vein was subsequently exposed and punctured with a 7-French
leak-proof sheath. Heparin (1.5 mg/kg) was introduced via the sheath. A
6-French pigtail catheter (Cordis, Johnson and Johnson, New Brunswick
City, NJ) was introduced through the right femoral vein sheath, and imaging
of the right ventricle and pulmonary valve was performed using digital sub-
traction angiography (DSA) (Siemens, Munich, Germany; Figure 3, A).
Pressure values for the right ventricle and main pulmonary artery were
also determined. The pulmonary valve was identified, and its position wasmarked according to imaging results. After measuring the radius of the pul-
monary valve, a valve stent of appropriate size was selected and loaded into
a 14-French sheath. A stent size larger than the measured annulus was se-
lected to ensure the avoidance of paravalvular leaks and in consideration
of the growth of the young sheep. The delivery route was established by in-
troducing a steel guide wire into the distal segment of the left or right pulmo-
nary valve via the pigtail catheter (see Figure 3, B). After the pigtail catheter
was removed, a 14-French delivery sheath with an expandable stub was de-
ployed into the main pulmonary artery via the guide wire (Shanghai Shape-
Memory Alloys Material Limited Company, Shanghai, China; Figure 3, C).
The expandable stub and steel guide wire were then removed, and the 14-
French sheath carrying the valve stent was connected with the delivery
sheath. The stent was inserted into the delivery sheath and the neck advanced
(under the DSA) to the previously marked position of the pulmonary valve
(Figure 3, D). After confirming that the stent had been delivered to the opti-
mal position, the delivery sheath was retracted to release the stent (Figure 3,
E). The delivery sheathwas subsequently removed and the right femoral vein
sutured. Imaging of the artificial pulmonary valve and the right ventricle was
performed by deploying a pigtail catheter via the left femoral vein (Figure 3,
F). Pressure values were recorded for the right ventricle and themain pulmo-
nary artery. The catheter and right femoral vein sheath were removed. Io-
hexol, up to 50 mL, was used as the contrast dye in the procedure.
All sheep received postoperative intramuscular injections of penicillin
(800,000 U) and subcutaneous injections of heparin (2500 IU) for 3 days.
Oral aspirin (3 mg/kg body weight) was given for 60 days.
Evaluation of Short-Term Efficacy of Valve Stent
Implantation
Immediately after implantation, chest color Doppler ultrasonography
was performed to assess right ventricular function and the hemodynamic
function of the artificial valve.
Evaluation of Valve Stent Implantation After 6
Months
All survivingsheepunderwent chest colorDoppler ultrasonography, 64-row
enhanced CT, and DSA 6 months after stent implantation. The right ventricle
and artificial valve were examined to assess functionality and hemodynamics.
One randomly selected sheep was killed by femoral artery bleeding. The
heart was collected, the right ventricle incised, and the position of the valve
stent noted. The stent was examined using electron microscopy.FIGURE 1. Pulmonary valve stent construction. A, The valve ring was made of supermalleable nitinol wire bent into 3 arc shapes. B, Three valve leaflets
were constructed by trimming porcine pericardium. The valve leaflets were sutured onto the valve ring. One side was denoted the attachment region and the
other, margo libra. C, The conduit-shaped stent comprised of the head, neck, and body. The head portion was proximal to the heart end, slightly protruded, and
trumpet shaped. The neck portion was thinner and connected the head portion with the body portion. The body portion was a straight tubular shape. The
artificial valve was placed within the tubular stent.
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DFIGURE 2. Placement of valved stent into sheath. A, The valved stent was crimped by hand to load into a 14-French sheath. B, The valved stent completely
crimped into the sheath.Efficacy of Repeated Valve Stent Implantation
Sixmonths after initial implantation, 2 randomly selected surviving sheep
had a repeated valve stent implantation via percutaneous DSA at the same
location as the initial implantation. The placement process was the same as
the initial implantation. Two months after surgery, follow-up color Doppler
ultrasonographywasperformedandvalvular function and locationexamined.
Statistical Analysis
Means, standard deviations, and minimum and maximums values are
given for continuous variables. Changes in heart rate, mean arterial pressure,
right ventricular pressure, pulmonary artery pressure, right ventricular
volume, right ventricular ejection fraction, transvalvular gradients, andeffective orifice areas over time (before implantation, 12 hours after implan-
tation, and 6 months after implantation) were compared using repeated
measurements. Moreover, Wilcoxon signed-rank test was performed to
compare the difference between the 2 time points postoperation due to non-
normally data. All statistical assessments were 2-sided and evaluated at the
0.05 level of significant difference. Statistical analyses were performed
using SPSS 15.0 statistical software (SPSS Inc, Chicago, Ill).
RESULTS
Operative Parameters
Valve stent implantation was not possible in 2 of
the 10 sheep. One of these animals had abnormally smallFIGURE 3. Valve stent implantation process (representative images). A, Imaging of the pulmonary valve was performed to measure the pulmonary valve
radius and location. B, Steel guide wires were deployed into the left or right pulmonary artery regions to facilitate delivery. C, A 14-French delivery sheath was
inserted into the pulmonary artery. D, The neck portion of the stent was delivered to the previously noted location of the pulmonary valve. E, The delivery
sheath was retracted and the stent released. F, Image of the artificial pulmonary valve revealing good placement and no regurgitation.
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Valve stent implantation was successful in the 8 other sheep.
The mean diameter of the pulmonary annulus was 14.2 
1.4 mm and 15.4  1.3 mm as revealed by Doppler ultra-
sound and angiography, respectively. The mean stent diam-
eter was 19.8  1.7 (range: 18–22 mm). Mean surgery
duration was 57.0  7.8 minutes (range: 48–70 minutes).
The mean x-ray exposure time was 10.6  2.3 minutes
(range: 7.2–13.4 minutes; Table 1).
Short-Term Efficacy Evaluation of Valve Stent
Implantation
In each case, the valve stent was immediately observable
under color Doppler ultrasonography following implanta-
tion. Artificial valve stents exhibited normal open and close
functionality with no evidence of stenosis or insufficiency
(data not shown). Heart rate was significantly increased after
stent implantation compared with before implantation
(P ¼ .042, Figure 4, A). There were no other differences
detected before and immediately after implantation for any
of the other heart functionmarkers examined (Figure 4,B–H).
Efficacy of Valve Stent Implantation After 6 Months
All sheep exhibited normal open and close valvular func-
tionality after 6 months, with no evidence of stenosis or
insufficiency apparent (Figure 5, A–D). Sixty-four-row CT
revealed accurate placement of the devices. Animals had
a weight gain of 8.2 to 13.5 kg. All heart function markers
were normal (ie, not different to preimplantation values; Fig-
ure 4, A–H). In all animals, no stent fracture, valve deforma-
tion or dislocation problems, or paravalvular leakage was
noted. Histologic dissection revealed a complete stent with
no evidence of fracture. Electron microscopy revealed that
TABLE 1. Surgical information of implantations performed on
experimental ewes
Pulmonary
annulus
US (mm)
Pulmonary
annulus
angiography
(mm)
Diameter
of stent
(mm)
Operation
time
(min)
Radiograph
exposure
time (min)
ID
1 13.5 14.6 18 54 9.2
2 12.2 13.2 18 65 11.1
3 16.3 17.2 22 70 13.4
4 14.3 15.4 20 50 12.5
5 15.3 16.7 22 48 7.2
6 12.4 14.2 18 62 12.1
7 15.2 16.1 20 53 7.9
10 14.6 15.8 20 54 11.5
Mean 14.23 15.40 19.75 57.00 10.61
SD 1.44 1.34 1.67 7.76 2.25
Minimum 12.2 13.2 18 48 7.2
Maximum 16.3 17.2 22 70 13.4
SD, Standard deviation; US, ultrasound.1366 The Journal of Thoracic and Cardiovascular Suthe stent was completely covered with endothelial cells
(see Figure 6, A and B).
Repeated Valve Stent Implantation
Ultrasonography revealed normal valvular open and close
function 2 months after repeated transplantation in both
sheep. One sheep exhibited mild pulmonary regurgitation
(Figure 7, A). Regurgitation was not apparent in the other
animal, cardiac function was normal, and there was no evi-
dence of valve stenosis (Figure 7, B).
DISCUSSION
Surgical reconstruction of the right ventricular outflow
tract, including valve implantation and pulmonary valve
replacement or repair, is clinically efficacious.14 However,
biologic valve deterioration often necessitates repeated
cardiopulmonary bypass surgery.15 To circumvent the risks
associated with multiple cardiopulmonary bypass surgeries,
percutaneous valve replacement has been developed in recent
years,16 providing patients with an alternative option. In this
study, we performed percutaneous femoral vein implantation
of the sheep pulmonary valve with a newly designed pulmo-
nary valve stent. The objective of our study was to evaluate
whether transcatheter implantation of the novel pulmonary
valve stent was achievable and to observe implantation effi-
cacy after 6months. Repeated pulmonary valve stent implan-
tation was also performed. Implantation of the device was
found to be highly successful and efficacious at 6 months
postsurgery. Repeated implantation was well tolerated.
The conduit-shaped stent developed in this study required
only 1 nitinol wire to be constructed without a connector,
exhibited good flexibility, and was capable of adapting to
the vessel after implantation. Electron microscope examina-
tion at 6 months postimplantation revealed that the stent was
fully covered by endothelial cells, evidencing complete
adherence. Because the intersecting region of the woven
stent allows vascular contraction and mild diastolic move-
ment, the likelihood of stent fracture should be reduced.
The fact that no cases of stent fracture were observed after
6 months supports this assertion. The trumpet-shaped head
portion of the stent consolidated placement at the pulmonary
orifice, and the adjoining, slightly thinner neck portion facil-
itated increased overall stent flexibility and prevented stent
deformation when the trumpet-shaped opening was pres-
sured. This design is capable of eliminating valve deforma-
tion and dislocation problems associated with the use
straight tubular stents, arising from compression at the pul-
monary orifice. The body portionwas conduit-shaped, allow-
ing for greater fixation due to the increased stent diameter.
Because the stent shapewaswell matchedwith the peripheral
valve configuration, the pulmonary valve was compressed
between the stent and the right ventricle wall, thus preventing
perivalvular leakage. This was substantiated through imag-
ing via color Doppler ultrasonography.rgery c June 2009
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DFIGURE 4. Heart function and hemodynamic markers before, immediately after, and 6 months after implantation. Heart rate (A), mean arterial pressure (B),
right ventricle pressure (C), pulmonary artery pressure (D), right ventricular volumes (E), right ventricle ejection fraction (F), transvalvular gradients (G), and
effective orifice areas (H) were assessed. *P< .05 between the indicated means.In this study, the artificial valve was sutured onto a nitinol
valve ring, as opposed to direct suture into the stent. This
made suturing of the valve into the conduit-shaped stent eas-
ier and firmer and resulted in the artificial valve being less
susceptible to deformation. This also guaranteed that the arti-
ficial valve remained on a flat surface, which better prevents
valve insufficiency and dislocation fromoccurring.We foundThe Journal of Thoracic and Cathat valvular and hemodynamic functions were normal
6 months postimplantation. Furthermore, there was no evi-
dence of increased thrombotic development on valve ring
structure following conventional anticoagulation therapy.
With regards to the materials used for artificial pulmonary
valve construction, previous studies have typically
reported use of the bovine jugular vein valve17,18 andrdiovascular Surgery c Volume 137, Number 6 1367
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DFIGURE 5. Pulmonary artery valve stent 6 months after implantation: color ultrasonography and computed tomography examination findings from a rep-
resentative animal. A, Artificial valve opening (white arrow).B, Artificial valve closing (white arrow).C, Color Doppler ultrasonography revealed no patterns
of blood passing or regurgitation. D, Right ventricular ejection fraction.polytetrafluoroethylene valve.19 The use of porcine pericar-
dium as a surgical biologic valve has a long history. We
used porcine pericardium as the material for valve construc-
tion in this study, applying surgical procedures to establish
the pericardium as a valve sutured onto a valvular ring. Por-
cine pericardium not only was easily obtained, but also had
larger valve diameter.
The design of the artificial valve was inspirited by bio-
logic valves in vivo. The function of valves was determined
by the design of valve ring. In combination with the trumpet-
shaped stent that provides a strong anchor, the valved stent is
functional as well. The woven design of the stent increasescompliance to avoid damage from contraction of the heart.
The design of the valve ring may assist in preventing post-
implantation deformity of the valve. The trumpet shape
and use of a slightly oversized stent ensure solid anchoring
of the stent and also avoid paravalvular leakage.
The surgical implantation technique used in this study
was similar to widely used techniques for intracoronary stent
implantation but different from implantation techniques
involving the fixation of the valve stent on the tip of a deliv-
ery sheath. Given that the stent-fixed delivery sheath is hard
and less flexible, damage to the heart may occur during the
curved passage from the inferior vena cava to the mainFIGURE 6. Six-month postoperative electron microscopy images of a stent. A, Nitinol wire covered by endothelial cells (magnification 1003). B, The stent
was completely covered by neatly arranged endothelial cells (magnification 15003).
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DFIGURE 7. Color Doppler ultrasonography examinations were performed 2 months after the second valve stent implantation. A, Spectral of the pulmonary
valve revealed mild regurgitation. B, Motion mode ultrasonography revealed normal cardiac function.pulmonary artery. In this study, we first introduced the deliv-
ery sheath into the pulmonary artery and then pushed the de-
vice through the sheath and into the pulmonary artery. This
allowed for safer passage, with no significant increase in x-
ray exposure time.
The life expectancy of biologic valves is an issue of signif-
icant concern. Once a valve deteriorates, replacement implan-
tation becomes necessary. Hence it is critical that valve stents
are amenable to repeated implantation. The valve stent
described in the current studyexhibited goodvascular compli-
ance upon secondary push delivery implantation and readily
overlappedwith the initial stent. No significant complications
were detected following repeated implantation.
This study had several limitations. First, the valve stent
could not be completely retrieved once released. Thus, fur-
ther modifications to the delivery system are needed to pro-
vide flexibility in cases of suboptimal placement and/or stent
size incompatibility. Such modifications will increase the
safety and reliability of this procedure. Second, the animal
cohort size was small and the follow-up time short. Last,
the use of a single sheep for histologic evaluation and the
lack of quantitative assessment of calcification are also lim-
itations. Additional studies, with larger cohorts and longer
follow-up durations, are needed to provide sufficient refer-
ence data for potential clinical application.
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